These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 16678930)

  • 1. Current impact of gene technology on healthcare. A map of economic assessments.
    Rogowski W
    Health Policy; 2007 Feb; 80(2):340-57. PubMed ID: 16678930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic testing and pharmacogenomics: issues for determining the impact to healthcare delivery and costs.
    Phillips KA; Veenstra DL; Ramsey SD; Van Bebber SL; Sakowski J
    Am J Manag Care; 2004 Jul; 10(7 Pt 1):425-32. PubMed ID: 15298364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and implementation of health technology assessment in Argentina: two steps forward and one step back.
    Rubinstein A; Pichon-Riviere A; Augustovski F
    Int J Technol Assess Health Care; 2009 Jul; 25 Suppl 1():260-9. PubMed ID: 19527545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Constructive Technology Assessment (CTA) as a tool in coverage with evidence development: the case of the 70-gene prognosis signature for breast cancer diagnostics.
    Retèl VP; Bueno-de-Mesquita JM; Hummel MJ; van de Vijver MJ; Douma KF; Karsenberg K; van Dam FS; van Krimpen C; Bellot FE; Roumen RM; Linn SC; van Harten WH
    Int J Technol Assess Health Care; 2009 Jan; 25(1):73-83. PubMed ID: 19126254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of economic evaluation to decision making in early phases of product development: a methodological and empirical review.
    Hartz S; John J
    Int J Technol Assess Health Care; 2008; 24(4):465-72. PubMed ID: 18828942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Approaches for economic evaluations of health care technologies.
    Tarride JE; Blackhouse G; Bischof M; McCarron EC; Lim M; Ferrusi IL; Xie F; Goeree R
    J Am Coll Radiol; 2009 May; 6(5):307-16. PubMed ID: 19394571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost modeling to justify technology acquisitions.
    Vanden Brink J; Gray S
    Healthc Financ Manage; 1997 Jun; 51(6):72-6. PubMed ID: 10167845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The science of health technology assessment--the economic perspective.
    Menon D
    Can J Clin Pharmacol; 2001; 8 Suppl A():17A-20A. PubMed ID: 11586373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics in clinical practice: considerations for testing.
    Constable S; Johnson MR; Pirmohamed M
    Expert Rev Mol Diagn; 2006 Mar; 6(2):193-205. PubMed ID: 16512779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cost-effectiveness evaluation of predictive molecular diagnostics using the example of hereditary non-polyposis colorectal cancer (HNPCC)].
    Hagen A; Hessabi HK; Gorenoi V; Schönermark MP
    Gesundheitswesen; 2008 Jan; 70(1):18-27. PubMed ID: 18273760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health system and equity perspectives in health technology assessment.
    Hanvoravongchai P
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S74-87. PubMed ID: 19253490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conditionally funded field evaluations and practical trial design within a health technology assessment framework.
    Bowen JM; Patterson LL; O'Reilly D; Hopkins RB; Blackhouse G; Burke N; Xie F; Tarride JE; Goeree R
    J Am Coll Radiol; 2009 May; 6(5):324-31. PubMed ID: 19394573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging technologies in healthcare: navigating risks, evaluating rewards.
    McGrady E; Conger S; Blanke S; Landry BJ
    J Healthc Manag; 2010; 55(5):353-64; discussion 364-5. PubMed ID: 21077584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The role of models in economic evaluation of healthcare].
    Rodríguez Barrios JM
    Farm Hosp; 2004; 28(4):231-42. PubMed ID: 15369433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical technology management: bridging the gap between theory and practice.
    Shemer J; Abadi-Korek I; Seifan A
    Isr Med Assoc J; 2005 Apr; 7(4):211-5. PubMed ID: 15847198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Historical development of health technology assessment in Thailand.
    Teerawattananon Y; Tantivess S; Yothasamut J; Kingkaew P; Chaisiri K
    Int J Technol Assess Health Care; 2009 Jul; 25 Suppl 1():241-52. PubMed ID: 19527543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A changing paradigm in the study and adoption of emerging health care technologies: coverage with evidence development.
    Wallner PE; Konski A
    J Am Coll Radiol; 2008 Nov; 5(11):1125-9. PubMed ID: 18954812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.